Declining or Ending Care After an Initial Psychiatric Evaluation: Obligations, Risks, and Best Practice
October 27, 2026
Introduction
Outpatient psychiatrists often see new patients whose needs exceed what their clinic can safely handle. Examples include dual diagnosis with active substance use, requests for several controlled substances, severe personality disorders needing intensive therapy, or patients who need a higher level of care. While physicians have considerable choice in whom they treat, this choice is limited by the duty not to abandon patients and not to discriminate.
This article reviews the ethical and clinical framework for declining or ending care, explains which decisions are defensible, and offers a practical protocol.
The Physician's Discretion and Its Limits
Physicians can end a patient-physician relationship for almost any reason, as long as it is legal, non-discriminatory, and does not immediately put the patient's safety at risk. The American College of Obstetricians and Gynecologists' ethics committee advises that doctors should not compromise their professional judgment just to meet patient requests. They also say that disagreeing with a doctor's recommendations is a less valid reason for discharge than safety concerns or a mismatch between patient needs and clinic services (Committee on Ethics, Obstetrics & Gynecology, 2022).
No formal tribunal reviews these decisions. However, you should document your reasoning, since licensing boards, payers, or courts may review it. The key question is whether your decision reflects the patient's clinical needs or simply who the patient is.
Abandonment Versus Appropriate Referral
Abandonment usually means ending an established relationship without giving reasonable notice, without allowing the patient to find another clinician, or when the patient's safety is at immediate risk. If you do a single consultative intake and make a documented referral, it typically does not create the ongoing relationship needed for abandonment to apply.
The duty to bridge prescriptions only applies to medications the psychiatrist has actually taken over. If the psychiatrist has not started prescribing, they are not required to continue controlled substances started by someone else or those they believe are unsafe. If the psychiatrist has taken over prescribing, stopping benzodiazepines suddenly is dangerous. It can cause seizures, delirium, and, in rare cases, death, so a gradual taper is recommended (Brunner et al., Journal of General Internal Medicine, 2025). The CDC also warns against suddenly stopping controlled medications in patients who are physically dependent (Dowell et al., MMWR Recommendations and Reports, 2022).
Discrimination Versus Clinical Scope
Making blanket exclusions by diagnosis, like saying "we don't treat personality disorders" or "we don't see people who use drugs," is the weakest position. Substance use disorder and other psychiatric conditions may be protected as disabilities. A systematic review of international guidance found that providers have often used personality disorder to exclude patients, and guidelines now discourage this (Wong et al., PLoS One, 2022). Guidance on co-occurring disorders supports integrated or coordinated care and warns against systems that exclude these patients (Alsuhaibani et al., BMC Psychiatry, 2021; Spencer et al., Pediatrics, 2021).
If you decide, after an individual assessment, that a patient needs a treatment your clinic does not offer, this is a defensible choice. For borderline personality disorder, psychotherapy like dialectical behavior therapy is the first-line treatment, and medication does not reliably treat the main symptoms (Leichsenring et al., JAMA, 2023; Bohus et al., Lancet, 2021). So, a clinic that only manages medications can reasonably refer a patient with repeated self-harm to a DBT program or an intensive outpatient program.
Defensible Versus Vulnerable Decisions
Severe personality disorder.
Defensible: "Needs DBT or IOP-level psychotherapy, which this clinic doesn't provide. Referral made."
Vulnerable: "We don't treat personality disorders."
Dual diagnosis.
Defensible: "Active SUD requires integrated addiction treatment outside this clinic's licensure. Referred to a dual-diagnosis program."
Vulnerable: discharge after a positive drug screen with no assessment or referral.
Multiple controlled substances.
Defensible: "Requested combination is unsafe. Alternatives offered. Prescribing not assumed. Referred to addiction psychiatry."
Vulnerable: "Patient disagreed with my plan."
Higher level of care.
Defensible: "Requires PHP or IOP. Warm handoff arranged."
Vulnerable: discharging an acutely suicidal patient as "too complex" (Newkirk et al., Current Psychiatry Reports, 2025).
Threats or violence.
Defensible: immediate dismissal with crisis resources provided (Prabhu et al., American Psychiatric Association resource document, 2019).
Vulnerable: discharging a patient for being "difficult" or for filing complaints.
Illustrative Case: Benzodiazepine and Alcohol Use Disorder
A primary care physician refers a patient with benzodiazepine and alcohol use disorders and a mood disorder after an unsuccessful outpatient taper. The receiving clinic is licensed only for mental health care, with no SUD licensure or detoxification expertise.
Turning down this patient is a scope-of-practice decision, not abandonment or discrimination. The joint benzodiazepine tapering guideline recommends treating co-occurring substance use disorder at the same time as the taper and referring patients to the right level of SUD care. It also suggests residential or medically managed settings if after-hours monitoring is needed (Brunner et al., Journal of General Internal Medicine, 2025). The American Psychiatric Association advises against using benzodiazepines in alcohol use disorder except for withdrawal management (Reus et al., American Psychiatric Association, 2018). Since a mental-health-only clinic cannot meet these standards, referral is likely the more responsible option.
The main risk is during the handoff. The primary care physician needs written confirmation that the clinic has not taken over prescribing and should continue prescribing until another program takes over.
Recommended Protocol
Document your clinical reasoning. Write down the patient's specific needs, the treatment that is indicated (such as DBT, MAT, IOP, or ASAM-level care), and the reasons your clinic cannot provide it.
Make sure prescribing responsibility is clear. State in writing whether you have taken over prescribing. If you have not, the referring prescriber remains responsible.
Make a specific referral by naming programs or levels of care. When appropriate, offer coordinated parallel care for the psychiatric condition.
Give written notice to the patient. Include crisis lines, emergency department instructions, and naloxone if needed.
Contact the referring physician and transfer records as soon as possible.
Check your local requirements, since state boards, payer contracts, and institutional policies can differ. Consult risk management or your malpractice carrier if needed.
Conclusion
Psychiatrists can decline or end care when a patient's needs are more than the clinic can provide. The decision is defensible when it is based on individual clinical need, includes a safe and specific transition, and does not leave the patient without care during acute risk. Clear documentation and direct communication about prescribing responsibility help ensure the process is seen as good patient care, not abandonment.
References
Ethical Approach for Managing Patient–Physician Conflict and Ending the Patient–Physician Relationship. Obstetrics and Gynecology. 2022. Committee on Ethics Guideline
Borderline Personality Disorder: A Review. The Journal of the American Medical Association. 2023. Leichsenring F, Heim N, Leweke F, et al. Review
Borderline Personality Disorder. Lancet. 2021. Bohus M, Stoffers-Winterling J, Sharp C, et al. Review
Evaluation of international guidance for the community treatment of ‘personality disorders’: A systematic review. PloS One. 2022. Zhan Yuen Wong N, Barnett P, Sheridan Rains L, Johnson S, Billings J. SR
Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. Journal of General Internal Medicine. 2025. Brunner E, Chen CA, Klein T, et al. Guideline
The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. American Psychiatric Association (2018). 2018. Victor I. Reus MD, Laura J. Fochtmann MD MBI, Oscar Bukstein MD MPH, et al. Guideline
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2022. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. Guideline
Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry. 2021. Alsuhaibani R, Smith DC, Lowrie R, Aljhani S, Paudyal V. SR
Principles of Care for Young Adults With Co-Occurring Psychiatric and Substance Use Disorders. Pediatrics. 2021. Spencer AE, Valentine SE, Sikov J, et al. Guideline